• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus.巴雷特食管早期癌症和高级别异型增生的手术与根治性内镜治疗对比
Cochrane Database Syst Rev. 2020 May 22;5(5):CD007334. doi: 10.1002/14651858.CD007334.pub5.
2
Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus.巴雷特食管早期癌症和高级别异型增生的手术与根治性内镜治疗对比
Cochrane Database Syst Rev. 2012 Nov 14;11:CD007334. doi: 10.1002/14651858.CD007334.pub4.
3
Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus.手术与根治性非手术治疗对巴雷特食管早期癌症和高级别异型增生的疗效比较
Cochrane Database Syst Rev. 2010 May 12(5):CD007334. doi: 10.1002/14651858.CD007334.pub3.
4
Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus.巴雷特食管早期癌症和高级别异型增生的手术与根治性内镜治疗对比
Cochrane Database Syst Rev. 2009 Apr 15(2):CD007334. doi: 10.1002/14651858.CD007334.pub2.
5
Management controversies in Barrett's oesophagus.巴雷特食管的管理争议。
J Gastroenterol. 2014 Feb;49(2):195-205. doi: 10.1007/s00535-013-0816-z. Epub 2013 Jun 5.
6
Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.完全性巴雷特食管根除性内镜黏膜切除术:治疗高级别异型增生和黏膜内癌的有效治疗方式——一项美国单中心经验
Am J Gastroenterol. 2009 Nov;104(11):2684-92. doi: 10.1038/ajg.2009.465. Epub 2009 Aug 18.
7
Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.巴雷特食管合并高级别异型增生或黏膜内癌患者初次内镜黏膜切除术标本中鳞状上皮下的高级病理学表现:对监测和内镜治疗管理的意义
Gastrointest Endosc. 2009 Sep;70(3):417-21. doi: 10.1016/j.gie.2009.01.047. Epub 2009 Jun 24.
8
[Barrett's esophagus: endoscopic treatment of high-grade dysplasia and early cancer].[巴雷特食管:高级别异型增生和早期癌症的内镜治疗]
Ned Tijdschr Geneeskd. 2003 Nov 15;147(46):2275-81.
9
Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients.169 例早期肿瘤患者行逐步根治性内镜切除术治疗 Barrett 食管。
Gut. 2010 Sep;59(9):1169-77. doi: 10.1136/gut.2010.210229. Epub 2010 Jun 4.
10
A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin.光动力疗法治疗癌前皮肤状况、巴雷特食管和胆道、脑、头颈部、肺、食管和皮肤癌症的系统评价。
Health Technol Assess. 2010 Jul;14(37):1-288. doi: 10.3310/hta14370.

引用本文的文献

1
The Influence of Different Treatment Strategies on the Long-Term Prognosis of T1 Stage Esophageal Cancer Patients.不同治疗策略对T1期食管癌患者长期预后的影响
Front Oncol. 2021 Oct 14;11:700088. doi: 10.3389/fonc.2021.700088. eCollection 2021.

本文引用的文献

1
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.基于德尔菲法的巴雷特食管异型增生和早期食管腺癌管理共识声明。
Gastroenterology. 2012 Aug;143(2):336-46. doi: 10.1053/j.gastro.2012.04.032. Epub 2012 Apr 24.
2
Endotherapy for Barrett's esophagus.内镜治疗 Barrett 食管。
Am J Gastroenterol. 2012 Jun;107(6):827-33. doi: 10.1038/ajg.2012.70.
3
Endoscopic therapies for the prevention and treatment of early esophageal neoplasia.内镜治疗在早期食管肿瘤的预防和治疗中的应用。
Expert Rev Gastroenterol Hepatol. 2011 Dec;5(6):731-43. doi: 10.1586/egh.11.80.
4
Outcomes of T1b esophageal adenocarcinoma patients.T1b 期食管腺癌患者的预后。
Gastrointest Endosc. 2011 Dec;74(6):1201-6. doi: 10.1016/j.gie.2011.08.006. Epub 2011 Oct 13.
5
Incidence of adenocarcinoma among patients with Barrett's esophagus.巴雷特食管患者腺癌的发病率。
N Engl J Med. 2011 Oct 13;365(15):1375-83. doi: 10.1056/NEJMoa1103042.
6
Comparison of endoscopic and surgical resection of intramucosal carcinoma in Barrett's esophagus.经内镜与手术切除 Barrett 食管黏膜内癌的对比。
Expert Rev Gastroenterol Hepatol. 2011 Oct;5(5):575-8. doi: 10.1586/egh.11.65.
7
Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.巴雷特食管患者恶性进展的风险:一项大型基于人群的研究结果。
J Natl Cancer Inst. 2011 Jul 6;103(13):1049-57. doi: 10.1093/jnci/djr203. Epub 2011 Jun 16.
8
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia.射频消融治疗 Barrett 食管伴异型增生的耐久性。
Gastroenterology. 2011 Aug;141(2):460-8. doi: 10.1053/j.gastro.2011.04.061. Epub 2011 May 6.
9
Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers.在两个高容量中心比较 Barrett 食管黏膜食管腺癌的内镜下和手术切除。
Ann Surg. 2011 Jul;254(1):67-72. doi: 10.1097/SLA.0b013e31821d4bf6.
10
The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens.T1 期食管腺癌患者淋巴结转移的患病率:食管切除术标本的回顾性分析。
Ann Surg. 2011 Feb;253(2):271-8. doi: 10.1097/SLA.0b013e3181fbad42.

巴雷特食管早期癌症和高级别异型增生的手术与根治性内镜治疗对比

Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus.

作者信息

Bennett Cathy, Green Susi, DeCaestecker John, Almond Max, Barr Hugh, Bhandari Pradeep, Ragunath Krish, Singh Rajvinder, Jankowski Janusz

机构信息

Centre for Innovative Research Across the Life Course (CIRAL), Coventry University, Coventry, UK.

Gastroenterology, Portsmouth Hospitals Trust, Cosham, UK.

出版信息

Cochrane Database Syst Rev. 2020 May 22;5(5):CD007334. doi: 10.1002/14651858.CD007334.pub5.

DOI:10.1002/14651858.CD007334.pub5
PMID:32442322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7390331/
Abstract

BACKGROUND

Barrett's oesophagus is one of the most common pre-malignant lesions in the world. Currently the mainstay of therapy is surgical management of advanced cancer but this has improved the five-year survival very little since the 1980s. As a consequence, improved survival relies on early detection through endoscopic surveillance programmes. Success of this strategy relies on the fact that late-stage pre-malignant lesions or very early cancers can be cured by intervention. Currently there is considerable controversy over which method is best: that is conventional open surgery or endotherapy (techniques involving endoscopy).

OBJECTIVES

We used data from randomised controlled trials (RCTs) to examine the effectiveness of endotherapies compared with surgery in people with Barrett's oesophagus, those with early neoplasias (defined as high-grade dysplasia (HGD) and those with early cancer (defined as carcinoma in-situ, superficially invasive, early cancer or superficial cancer T-1m (T1-a) and T-1sm (T1-b)).

SEARCH METHODS

We used the Cochrane highly sensitive search strategy to identify RCTs in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), ISI Web of Science, EBMR, Controlled Trials mRCT and ISRCTN, and LILACS, in July and August 2008. The searches were updated in 2009 and again in April 2012.

SELECTION CRITERIA

Types of studies: RCTs comparing endotherapies with surgery in the treatment of high-grade dysplasia or early cancer. All cellular types of cancer were included (i.e. adenocarcinomas, squamous cell carcinomas and more unusual types) but will be discussed separately.

TYPES OF PARTICIPANTS

patients of any age and either gender with a histologically confirmed diagnosis of early neoplasia (HGD and early cancer) in Barrett's or squamous lined oesophagus. Types of interventions; endotherapies (the intervention) compared with surgery (the control), all with curative intent.

DATA COLLECTION AND ANALYSIS

Reports of studies that meet the inclusion criteria for this review would have been analysed using the methods detailed in Appendix 9.

MAIN RESULTS

We did not identify any studies that met the inclusion criteria. In total we excluded 13 studies that were not RCTs but that compared surgery and endotherapies.

AUTHORS' CONCLUSIONS: This Cochrane review has indicated that there are no RCTs to compare management options in this vital area, therefore trials should be undertaken as a matter of urgency. The problems with such randomised methods are standardising surgery and endotherapies in all sites, standardising histopathology in all centres, assessing which patients are fit or unfit for surgery and making sure there are relevant outcomes for the study (i.e. long-term survival (over five or more years)) and no progression of HGD.

摘要

背景

巴雷特食管是全球最常见的癌前病变之一。目前,主要的治疗方法是对晚期癌症进行手术治疗,但自20世纪80年代以来,这对五年生存率的改善甚微。因此,提高生存率依赖于通过内镜监测计划进行早期检测。该策略的成功依赖于晚期癌前病变或极早期癌症可通过干预治愈这一事实。目前,关于哪种方法最佳存在相当大的争议:即传统的开放手术还是内镜治疗(涉及内镜的技术)。

目的

我们使用随机对照试验(RCT)的数据,比较内镜治疗与手术治疗在巴雷特食管患者、早期肿瘤形成患者(定义为高级别上皮内瘤变(HGD))以及早期癌症患者(定义为原位癌、浅表浸润癌、早期癌或浅表癌T-1m(T1-a)和T-1sm(T1-b))中的有效性。

检索方法

我们于2008年7月和8月使用Cochrane高灵敏度检索策略,在MEDLINE、EMBASE、Cochrane对照试验中央注册库(CENTRAL)、科学引文索引(ISI)网络数据库、循证医学图书馆(EBMR)、对照试验注册库(mRCT)、国际标准随机对照试验编号注册库(ISRCTN)以及拉丁美洲和加勒比卫生科学数据库(LILACS)中检索RCT。检索在2009年更新,并于2012年4月再次更新。

入选标准

研究类型:比较内镜治疗与手术治疗高级别上皮内瘤变或早期癌症的RCT。纳入所有细胞类型的癌症(即腺癌、鳞状细胞癌和更罕见的类型),但将分别进行讨论。

研究对象类型

任何年龄和性别的患者,经组织学确诊为巴雷特食管或鳞状上皮食管的早期肿瘤形成(HGD和早期癌症)。干预类型:内镜治疗(干预措施)与手术治疗(对照措施),均具有治愈意图。

数据收集与分析

符合本综述纳入标准的研究报告将使用附录9中详述的方法进行分析。

主要结果

我们未找到任何符合纳入标准的研究。总共排除了13项非RCT但比较手术和内镜治疗的研究。

作者结论

本Cochrane综述表明,在这个关键领域没有RCT来比较治疗方案,因此应紧急开展试验。此类随机方法存在的问题包括在所有部位使手术和内镜治疗标准化、在所有中心使组织病理学标准化、评估哪些患者适合或不适合手术以及确保研究有相关结局(即长期生存(超过五年或更长时间))且HGD无进展。